2-phenoxy pyrimidinone analogues

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S263220, C514S263340, C514S260100, C514S264100, C544S269000, C544S267000, C544S278000, C544S262000, C544S279000

Reexamination Certificate

active

08003656

ABSTRACT:
2-Phenoxy pyrimidinone analogues are provided, of the Formula:wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

REFERENCES:
patent: 5124331 (1992-06-01), Arita et al.
patent: 5202328 (1993-04-01), de Laszlo et al.
patent: 5962457 (1999-10-01), Chenard et al.
patent: 6136812 (2000-10-01), Chenard et al.
patent: 6323208 (2001-11-01), Chenard et al.
patent: 6921764 (2005-07-01), Chenard et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2004/0132732 (2004-07-01), Han et al.
patent: 2004/0242566 (2004-12-01), Feng et al.
patent: 2005/0165049 (2005-07-01), Hulme et al.
patent: 2007/0135454 (2007-06-01), Bayliss et al.
patent: 2008/0090845 (2008-04-01), Blum et al.
patent: 2010/0008866 (2010-01-01), Blum et al.
patent: WO-98/49899 (1998-11-01), None
patent: WO-02/26718 (2002-04-01), None
patent: WO-02/076946 (2002-10-01), None
patent: WO-03/106435 (2003-12-01), None
patent: WO-2004/033435 (2004-04-01), None
patent: WO-2004/037176 (2004-05-01), None
patent: WO-2005/049601 (2005-06-01), None
patent: WO-2005/049613 (2005-06-01), None
patent: WO-2005/120510 (2005-12-01), None
patent: WO-2006/047516 (2006-05-01), None
patent: WO-2006/120481 (2006-11-01), None
patent: WO2006/122200 (2006-11-01), None
patent: WO-2006/122200 (2006-11-01), None
patent: WO-2007/056124 (2007-05-01), None
patent: WO-2008/156607 (2008-12-01), None
patent: WO-2009/100403 (2009-08-01), None
patent: WO-2009/121036 (2009-10-01), None
Vippagunta, S.R., Adv. Drug. Delivery Rev., 2001, 48, p. 3-26.
The International Search Report and Written Opinion dated Sep. 8, 2008, from corresponding PCT Application No. PCT/US07/18654.
Opposition filed in the name of Asociacion de la Industria Farmacéutica Nacional Asifan dated Jul. 21, 2009, in corresponding Costa Rica Patent Application No. 10675 (English translation).
Johansen, M. E., et al., “TRPV1 Antagonists Elevate Cell Surface Populations of Receptor Protein and Exacerbate TRPV1-Mediated Toxicities in Human Lung Epithelial Cells,” Toxicological Sciences, 89(1), 278-286 (2006) (Advance Access publication Aug. 24, 2005).
Thomas, Karen C. et al., “Transient Receptor Potential Vanilloid 1 Agonists Cause Endoplasmic Reticulum Stress and Cell Death in Human Lung Cells”, The Journal of Pharmacology and Experimental Therapeutics, vol. 321, pp. 830-838, (2007).
Bolcskei, Kata et al.,“Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice,” Pain 117, pp. 368-376, (2005).
Helyes, Zsuzsanna et al., “Role of transient receptor potential vanilloid 1 receptors in endotoxin-induced airway inflammation in the mouse,” Am J Physiol Lung Cell Mol Physiol., vol. 292, pp. L1173-81, (2007).
Banvolgyi, Agnes et al., “Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model,” J. Neuroimmunology, vol. 169, pp. 86-96, (2005).
U.S. Appl. No. 11/895,266, Blum et al.
Anquetin, G. et al., “Synthesis of New Fluoroquinolones and Evaluation of their in Vitro Activity on Toxoplasma Gondii and Plasmodium spp.,” Bioorganic & Medicinal Chemistry Letters, vol. 14, pp. 2773-2776, (2004).
Sako, Magoichi et al., “New and Facile Synthesis of 5,6,7,8-Tetrahydro-5-deaza-5-thiapterins via the Aliphatic S-NType Smiles Rearrangement,” Chem. Pharm. Bull., vol. 42(4), pp. 806-810, (1994).
Rokosz, Laura, “Discovery and Development of Melanin-Concentrating Hormone Receptor 1 antagonists for the Treatment of Obesity,” Expert Opin. Drug Discov., vol. 2(10), pp. 1301-1327, (2007).
McNaught et al., “cycloalkyl groups”, IUPAC Ed, [Online] Jan. 1, 1997, Compendium of Chemical Terminology: IUPAC Recommendations; [IUPAC Chemical Data Series], Blackwell Science, Oxford [U.A.], XP002585006, ISBN: 978-0-86542-684-9 Retrieved from the Internet: URL:http://www.iupac.org/goldbook/C01498.pdf>.
McNaught et al., “alkyl groups”, IUPAC Ed, [Online], Jan. 1, 1997, Compendium of Chemical Terminology: Iupac Recommendations; [IUPAC Chemical Data Series], Blackwell Science, Oxford [U.A.], XP002585005, ISBN: 978-0-86542-684-9, Retrieved from the Internet: URL:http://www.iupac.org/goldbook/A00228.pdf>.
Supplementary European Search Report and Opinion dated Aug. 10, 2010, in corresponding European Application No. 07811503.7.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

2-phenoxy pyrimidinone analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-phenoxy pyrimidinone analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-phenoxy pyrimidinone analogues will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2713094

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.